RSV

RSV Vaccine Approved for Adults 50 and Up: What You Need to Know Before Getting the Shot

by

London, United Kingdom – The Food and Drug Administration has granted approval for GSK’s respiratory syncytial virus vaccine to be administered to individuals as young as 50 years old, particularly those at a higher risk of severe RSV. This decision marks the first time a vaccine has been authorized for use in this age group to combat RSV. GSK, a global vaccine and drug manufacturer, formally requested the FDA in February to extend approval to …

Read more

RSV Vaccine Breakthrough: Thousands of Seniors Saved by Game-Changing GSK Shot!

by

Atlanta, Georgia – Respiratory syncytial virus (RSV) poses a significant threat to seniors, leading to numerous hospitalizations and deaths every year. However, recent data from the Centers for Disease Control and Prevention also highlight the severe impact of RSV on adults aged 50 and above, particularly those with underlying chronic conditions such as asthma, diabetes, and congestive heart failure. According to Phil Dormitzer, GSK’s head of vaccines research and development and infectious disease research, approximately …

Read more

Vaccines Battle: Moderna Gears Up for RSV Approval Against Pfizer and GSK – Will They Dominate?

by

Boston, MA – Vaccines have been at the forefront of medical innovation in recent years, with the approval of new shots offering hope for tackling a range of diseases. Moderna, a biotech company based in Boston, Massachusetts, has recently received approval for its shot targeting respiratory syncytial virus (RSV) in older adults. This approval marks a significant step in the company’s efforts to expand its messenger RNA platform beyond just Covid treatments. The Centers for …

Read more

Approval Imminent: Moderna Set to Launch RSV Shot in U.S. Market After Success of Covid Vaccine

by

Boston, Massachusetts – Moderna is on the cusp of an important milestone as investors eagerly await the approval of its RSV vaccine, marking a potential comeback from its struggles during the COVID-19 pandemic last year. The company’s RSV shot, if authorized, would be its second product to enter the market in the United States following the success of its COVID-19 vaccine. This would also make Moderna the third company to introduce an RSV vaccine, after …

Read more